Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4228967 | 1.00 | CYP1A2 (0.32) | CYP1A2NPC1MAPTRAB9AKMT2A | |
| SCHEMBL4227068 | 0.94 | CYP1A2 (0.35) | CYP1A2NPC1MAPTRAB9AKMT2A | |
| SCHEMBL4227066 | 0.94 | CYP1A2 (0.35) | CYP1A2NPC1MAPTRAB9AKMT2A | |
| SCHEMBL4227874 | 0.84 | CYP2C9 (0.45) | CYP1A2NPC1MAPTRAB9AKMT2A | |
| SCHEMBL4227868 | 0.84 | CYP2C9 (0.45) | CYP1A2NPC1MAPTRAB9AKMT2A | |
| SCHEMBL4232677 | 0.84 | NPSR1 (0.33) | CYP1A2NPC1MAPTRAB9AKMT2A | |
| SCHEMBL4232675 | 0.84 | NPSR1 (0.33) | CYP1A2NPC1MAPTRAB9AKMT2A | |
| SCHEMBL4222550 | 0.83 | HSD11B1 (0.44) | CYP1A2NPC1MAPTRAB9AKMT2A | |
| SCHEMBL4237370 | 0.83 | EGFR (0.38) | CYP1A2NPC1MAPTRAB9AKMT2A | |
| SCHEMBL4222553 | 0.83 | HSD11B1 (0.44) | CYP1A2NPC1MAPTRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062401-A1 | DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | UNIVERSITAT DORTMUND (DE) | 2009-03-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062401-A1 | DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | CHAT, DLAT, CPT1A | CYP1A2 2000/4885NPC1 584/4885MAPT 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.